title: [Current treatment strategies for follicular lymphoma].
abstract: In the last few years major changes have taken place in the management of follicular lymphoma (FL) leading to a substantial improvement in the prognosis of patients suffering from this disease. For patients with limited disease stages I and II radiotherapy can lead to long-term remission, while it still remains unclear whether this actually represents a cure; therefore, new approaches are investigating the combination of irradiation with an anti-CD20 antibody. For patients with advanced stages III and IV and a low tumor burden, watch and wait is still the first choice of management. For advanced stages III and IV and a high tumor burden, immunochemotherapy followed by 2 years of rituximab maintenance therapy is the worldwide accepted standard. New antibodies and new agents targeting oncogenic pathways or having immunomodulatory activity provide attractive new therapeutic options, which are currently being explored in clinical phase II/III studies. These approaches provide the perspective to establish chemotherapy-free therapy concepts in the near future.
authors: Klinikum der Universität München, Campus Großhadern, Medizinische Klinik und Poliklinik III, Marchioninistr. 15, 81377, München, Deutschland. wolfgang.hiddemann@med.uni-muenchen.de.
authors: W
authors: W
authors: Hiddemann
authors: Klinikum der Universität München, Campus Großhadern, Medizinische Klinik und Poliklinik III, Marchioninistr. 15, 81377, München, Deutschland.
authors: E
authors: E
authors: Hoster
authors: Klinikum der Universität München, Campus Großhadern, Medizinische Klinik und Poliklinik III, Marchioninistr. 15, 81377, München, Deutschland.
authors: C
authors: C
authors: Schmidt
authors: Klinikum der Universität München, Campus Großhadern, Medizinische Klinik und Poliklinik III, Marchioninistr. 15, 81377, München, Deutschland.
authors: M
authors: M
authors: Dreyling
authors: Klinikum der Universität München, Campus Großhadern, Medizinische Klinik und Poliklinik III, Marchioninistr. 15, 81377, München, Deutschland.
authors: M
authors: M
authors: Unterhalt
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D059248:Chemoradiotherapy / Q000379:methods*; D003131:Combined Modality Therapy / Q000379:methods; D019317:Evidence-Based Medicine; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008224:Lymphoma, Follicular / Q000473:pathology* / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods*; D011878:Radiotherapy / Q000379:methods; D000069283:Rituximab / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000069283:Rituximab
keywords: Antibodies; Follicular lymphoma, chemotherapy; Follicular lymphoma, immunotherapy; Follicular lymphoma, radiotherapy; Immunomodulation